This technology determines the efficacy of dynamic cellular reaction against target compounds within one hour after the compound is added. According to the comany, the method will contribute
Cogane demonstrated positive results in preclinical in vitro and in vivo models of ALS. There is an ongoing study of Cogane in the genetic ‘gold standard’ in vivo
The brands include Atopiclair and Papulex. Atopiclair, used to treat atopic dermatitis, has been launched in Hong Kong, Malaysia, Singapore and India, while Papulex, which is used to
Discover-2 is a randomized, double-blind, double-dummy study conducted in patients randomized to vancomycin allowed to switch to oral linezolid after three days of IV vancomycin therapy. The study
Regional distributors join InVitria’s worldwide distributors including Sigma-Aldrich and Thermo Fisher Scientific. The company’s distribution network will provide regional distribution options for customers in North America, Europe, Asia,
Elsevier’s External link e-learning ICD-10 comprises ICD-10 Roadmap and educational resources, that will be integrated into Care Communications’ offerings. The ICD-10 Roadmap is divided into four phases of
APN301 is a recombinant fusion protein consisting of the humanized anti-GD2 monoclonal antibody hu14.18 fused to the cytokine interleukin-2 (IL2). APN301 will be administered along with GM-CSF and
AL-408 has been proven to have potent neuroprotective effects in a number of in vitro and in vivo models of neurotoxicity, the data from pre-clinical studies says. In
Aptiv Solutions will manage the Galena Phase 3 trial, PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment). The
Lodotra, which is currently approved for marketing in 16 European countries is a modified (delayed)-release formulation of low-dose prednisone. Circadian Administration of Prednisone in RA (CAPRA-2), 12-week, double-blind,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.